SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. filed an 8-K with the Securities and Exchange Commission on January 3, 2024, under the ticker BCYP — the legacy identifier of Big Cypress Acquisition Corp, the blank-check vehicle through which it went public. Big Cypress Acquisition Corp completed its initial public offering in 2021, targeting the healthcare and life sciences sector, and subsequently completed a business combination with SAB Biotherapeutics, a clinical-stage biopharmaceutical company focused on human polyclonal antibody therapeutics. The combined entity has continued its SEC reporting obligations following the de-SPAC transaction. For complete filing history, deal data, and real-time monitoring across the SPAC universe, sign up for full access at SpacDesk.